Possible Protective Effect of Rosuvastatin in Chemotherapy-Induced Cardiotoxicity in HER2 Positive Breast Cancer Patients: A Randomized Controlled Trial
Summary
Chemotherapy in HER2 positive breast cancer patients can lead to cardiotoxicity. This study investigated the potential protective effect of rosuvastatin against chemotherapy-induced cardiotoxicity. The results showed that rosuvastatin-treated group had significantly lower decline in LVEF, lower levels of hs-cTnI, IL-6, and MPO, and no cases of cardiotoxicity compared to the control group. This suggests that rosuvastatin may be a promising protective agent against chemotherapy-induced cardiotoxicity.
Practical Solutions and Value
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, helping to extend the benefits of clinical trials into everyday medical practice.
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routines.
Learn more about how we can help at aidevmd.com.
